I like some of Fujifilm’s cameras. But what does it know about pharmaceuticals?

Well, a lot actually.

And on Sept. 24, its drug manufacturing arm Fujifilm Biotechnologies made its next big investment: a $3.2 billion facility in Holly Springs, North Carolina, part of the state’s biotech hub—aka the Research Triangle.

Fujifilm Biotechnologies launched as a drug manufacturer in 2011, making a big shift into healthcare as its film business was failing. Over the last almost 15 years, the company has found success in this model, reporting $2.1 billion in revenue for its healthcare segment in Q4 2025.

A new industry. In 2006, Fujifilm lost a significant portion of its revenue when digital cameras took over and the company could no longer make as much profit from physical film, Lars Petersen, president and CEO of Fujifilm Biotechnologies, told Healthcare Brew.

The camera maker isn’t new to biotech, but it is expanding.—CM

It’s no secret US drug prices are much higher than the rest of the world—nearly 2.8x higher for branded and generics in 2022, in fact, the Department of Health and Human Services reported.

President Trump has been outspoken about the cost of drugs in the US, and health research organization KFF reported over half of adults in the country are “very worried” or “somewhat worried” about affording their prescription medications.

Both public and private solutions have come forward to address these expenses, including the $35 insulin cap established in the Inflation Reduction Act or drug discount companies creating initiatives like GoodRx’s couponing and direct-to-consumer (DTC) options like billionaire Mark Cuban’s Cost Plus Drugs.

On Sept. 30, the Trump administration announced a new public-private program to lower drug costs. Called TrumpRx, the partnership with pharma giant Pfizer intends to sell drugs directly to patients at prices 40%–85% cheaper than usual and doesn’t go through insurance, according to press releases.

Here’s how TrumpRx stacks up to current DTC offerings.—CM

Whether you’re a doctor checking on the devices you use, a manufacturer learning from others’ mistakes, or you just like drama, you need to know about recent FDA medical device recalls.

Every year, the FDA gets 2+ million reports of deaths, injuries, and malfunctions suspected of being linked to medical devices. The agency then issues recalls with corrections ranging from making tweaks to pulling a device off the market.

Healthcare Brew provides a monthly summary of some recent Class I recalls, the most dangerous kind.

Without further ado, here is September’s Recall Roundup!

Bent out of shape. Several components of Medtronic Cardiac Surgery’s DLP left heart ventricle catheter have been recalled because the catheters “may not retain their shape.” Medtronic told users to quarantine affected lots.

See the full list here.—CC

Real jobs, shared through real communities. CollabWORK brings opportunities directly to Healthcare Brew readers—no mass postings, no clutter, just roles worth seeing. Click here to view the full job board.

• Clinical Administrator, Nursing Supervisor Department of Nursing at Medstar Health (in person)
• Chief Medical Information Officer at Memorial Sloan-Kettering Cancer Center (in person)
• Chief Nursing Officer at Encompass Health (in person)
• Clinical Supervisor at Health Connect America (in person)
• RN | Director at St. David’s North Austin Medical Center (in person)

The feeling of getting a 5/5 on the Brew’s weekly news quiz has been compared to getting a company-wide shoutout from your boss. It’s that satisfying.